Alivus Life Sciences (ALIVUS) Stock Overview
Develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
ALIVUS Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Alivus Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹919.75 |
| 52 Week High | ₹1,225.10 |
| 52 Week Low | ₹819.00 |
| Beta | 0.074 |
| 1 Month Change | -1.36% |
| 3 Month Change | 4.68% |
| 1 Year Change | -11.29% |
| 3 Year Change | 141.28% |
| 5 Year Change | n/a |
| Change since IPO | 22.88% |
Recent News & Updates
Shareholder Returns
| ALIVUS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.6% | -0.1% | -3.0% |
| 1Y | -11.3% | 6.8% | 7.8% |
Return vs Industry: ALIVUS underperformed the Indian Pharmaceuticals industry which returned 6.8% over the past year.
Return vs Market: ALIVUS underperformed the Indian Market which returned 7.8% over the past year.
Price Volatility
| ALIVUS volatility | |
|---|---|
| ALIVUS Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: ALIVUS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ALIVUS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,203 | Yasir Rawjee | www.alivus.com |
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.
Alivus Life Sciences Limited Fundamentals Summary
| ALIVUS fundamental statistics | |
|---|---|
| Market cap | ₹112.89b |
| Earnings (TTM) | ₹5.44b |
| Revenue (TTM) | ₹25.12b |
Is ALIVUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALIVUS income statement (TTM) | |
|---|---|
| Revenue | ₹25.12b |
| Cost of Revenue | ₹11.28b |
| Gross Profit | ₹13.84b |
| Other Expenses | ₹8.40b |
| Earnings | ₹5.44b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 44.30 |
| Gross Margin | 55.09% |
| Net Profit Margin | 21.64% |
| Debt/Equity Ratio | 2.0% |
How did ALIVUS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 01:12 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alivus Life Sciences Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neha Manpuria | BofA Global Research |
| Prathamesh Masdekar | BP Wealth Management Private Limited |
| Nitin Agarwal | DAM Capital Advisors |